Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial-Reference-Cited by-同舟云学术

Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

Published:2016-10 Issue:2 Volume:96 Page:341-348
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Zapatero Almudena,Guerrero Araceli,Maldonado Xavier,Álvarez Ana,González-San Segundo Carmen,Cabeza Rodriguez Maria Angeles,Macías Victor,Pedro Olive Agustí,Casas Francesc,Boladeras Ana,Martín de Vidales Carmen,Vázquez de la Torre Maria Luisa,Calvo Felipe A.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference34 articles.

1. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study;Bolla;Lancet Oncol,2010

2. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer;Horwitz;J Clin Oncol,2008

3. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial;D'Amico;JAMA,2008

4. High-dose radiotherapy with short-term or long-term androgen deprivation in localized prostate cancer (DART 01/05 GICOR): A randomized, controlled, phase 3 trial;Zapatero;Lancet Oncol,2015

5. Intensity-modulated radiation therapy: Supportive data for prostate cancer;Cahlon;Semin Radiat Oncol,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

2. Significance of androgen‐deprivation therapy for intermediate‐ and high‐risk prostate cancer treated with high‐dose radiotherapy: A literature review;International Journal of Urology;2024-07-17

3. Bedeutung der Dauer einer begleitenden Hormontherapie zur definitiven Strahlentherapie;Die Urologie;2022-10-19

4. Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis;The Prostate;2022-08

5. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial;The Lancet Oncology;2022-05